<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR>               <BR>               <BR>                  <BR>                     <BR>                        Metoprolol succinate is a beta1-selective adrenoceptor blocking agent. <BR>Metoprolol succinate extended-release tablets USP are indicated for the treatment of: <BR>                        <BR>                           Hypertension (1.1) <BR><BR>                           <BR>                           Angina Pectoris (1.2) <BR><BR>                           <BR>                           Heart Failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.(1.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.1 <BR>                        Hypertension<BR>                         <BR>                     <BR>                     <BR>                        Metoprolol succinate extended-release tablets USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents [see <BR>                           <BR>                              Dosage and Administration (2)<BR>                           <BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.2 <BR>                        Angina Pectoris<BR>                         <BR>                     <BR>                     <BR>                        Metoprolol succinate extended-release tablets USP are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.3 <BR>                        Heart Failure<BR>                     <BR>                     <BR>                        Metoprolol succinate extended-release tablets USP are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>